FPI-2265 is under clinical development by Fusion Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase III drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback